For sufferers with superior non-small cell lung most cancers who progressed on two or extra prior regimens, THIO with Libtayo elicited optimistic responses: © inventory.adobe.com.
Amongst sufferers with superior non-small cell lung most cancers whose illness has progressed on two or extra prior standard-of-care remedy regimens, the remedy mixture of THIO (ateganosine) sequenced with the immune checkpoint inhibitor Libtayo (cemiplimab) elicited optimistic responses in accordance with medical trial information.
Findings from the section 2 THIO-101 medical trial had been introduced by the clinical-stage biopharmaceutical firm MAIA Biotechnology in a information launch.
As of June 30, 2025, the estimated median progression-free survival in third-line remedy with THIO and Libtayo was 5.6 months, with the comparable threshold in standard-of-care therapies being 2.5 months, in accordance with the information launch. As well as, the estimated median total survival was 17.8 months. The information launch additional famous that throughout all sufferers in all remedy traces, two sufferers had accomplished 33 cycles of remedy, which speaks to THIO’s potential for prolonged dosing.
“THIO-101 continues to disclose spectacular efficacy with noticed progression-free survival of 5.6 months, which is greater than double the standard-of-care [progression-free survival] of simply 2.5 months. The info additionally exhibit the sturdiness of [THIO] remedy by means of prolonged remedy cycles, which is according to constant tolerability and low toxicity,” stated MAIA Chairman and CEO Dr. Vlad Vitoc in a press release included within the information launch. “We’re in search of additional validation of [THIO]’s sturdy efficacy in our THIO-101 section 2 growth trial, which started enrolling sufferers in July 2025.”
Extra About THIO From WCLC
CURE just lately sat down with Dr. Thomas Jankowski, a medical oncologist on the Medical College of Lubin in Poland, for an interview through the 2025 IASLC World Convention on Lung Most cancers in Barcelona, to debate the science behind THIO.
“We reside in an period of immunotherapy with checkpoint inhibitors, which have proven superb outcomes, together with lengthy total survival and progression-free survival,” stated Jankowski. “Nonetheless, some sufferers nonetheless expertise illness development. At the moment, second-line remedy for these sufferers is barely chemotherapy. There isn’t any established immunotherapy after immunotherapy but, though many trials are specializing in this. Proper now, we don’t have immunotherapy choices for sufferers who progress after prior immunotherapy, so we’re searching for new medication, particularly for sufferers in second, third or later traces of remedy.
“Our drug, THIO, is a telomerase inhibitor. It’s a sort of chemotherapy, however in our challenge, we use solely very restricted, small doses. We use THIO not for its chemotherapy impact, however to beat resistance to immunotherapy with checkpoint inhibitors. That’s the reason we mix THIO with immunotherapy in our trial.
“We use Libtayo as one of many immunotherapy medication as a result of now we have a collaboration with its producer. Nonetheless, I imagine it might be mixed with any immunotherapy drug, both anti-PD-1 or anti-PD-L1. We even have trials in different cancers utilizing completely different immune checkpoint inhibitors. On this trial, we’re utilizing Libtayo.”
Extra Concerning the THIO-101 Scientific Trial
The THIO-101 medical trial is a four-part, open-label, multicenter examine evaluating the protection and effectiveness of various doses of THIO sequenced with mounted doses of Libtayo amongst sufferers with superior non-small cell lung most cancers who had progressed, discontinued attributable to toxicity, or relapsed after receiving prior remedy with an anti-PD-1/PD-L1 remedy, in accordance with the trial’s itemizing on clinicaltrials.gov.
The trial, which is being performed at 33 worldwide websites, is presently recruiting sufferers, in accordance with the itemizing. With an estimated eventual enrollment of 227 sufferers, the trial has an approximate major completion date of June 30, 2026, and an estimated examine completion date of Dec. 31, 2026, in accordance with the itemizing.
References
- “MAIA Biotechnology Highlights Optimistic Efficacy Knowledge from THIO-101 Section 2 Scientific Trial in Non-Small Cell Lung Most cancers,” information launch, Sept. 11, 2025; https://ir.maiabiotech.com/news-events/press-releases/element/150/maia-biotechnology-highlights-positive-efficacy-data-from
- “Research Explores THIO Plus Immunotherapy in Superior Lung Most cancers,” CURE, Sept. 12, 2025; https://www.curetoday.com/view/study-explores-thio-plus-immunotherapy-in-advanced-lung-cancer
- “THIO Sequenced With Cemiplimab in Superior NSCLC;” https://clinicaltrials.gov/examine/NCT05208944#study-overview
For extra information on most cancers updates, analysis and schooling, don’t overlook to subscribe to CURE®’s newsletters right here.
